Our Grants and Supported Research Areas

Part the Cloud offers two types of grants, the Translational Research Grant Program and Challenges.

The Translational Research Grant Program focuses on the most exciting science in the dementia field that is ready for early trials. These grants are awarded annually. Research areas include metabolic function; cell signaling and communication; cell senescence; immune response, misfolded proteins and growth factors; amyloid and tau related; vascular and oxidative stress related; and genome sequencing.

Challenges focus on a specific topic.

Gene Targeting (2024 Challenge)

The Part the Cloud Gene Targeting Challenge aims to supercharge the development of therapies tailored to the genetic underpinnings of Alzheimer’s disease by supporting new and ongoing early-stage clinical trials using gene targeting. Five million dollars was awarded to four clinical trials to advance personalized gene editing and gene-related therapies.

Part the Cloud + Bill Gates Partnership (2020 Challenge)

Bill Gates joined the Alzheimer's Association Part the Cloud Grant Program in a shared vision for innovation by making a $10 million award. The Alzheimer's Association worked through Part the Cloud to raise $20 million, doubling the total clinical research investment to over $60 million. This partnership will help propel 19 high-risk, high-reward research projects aimed at potential new treatments and devices for Alzheimer's and dementia. From 128 ideas submitted from 18 countries, over $30 million was awarded to 19 researchers to further develop their proposals over 3 years.

RESCUE and Neurodegeneration Research Area (2018 Challenge)

The Part the Cloud to RESCUE (REverse, reStore, Cease and UndErstand) Brain Cell Degeneration in Alzheimer's disease challenge aims to accelerate the discovery and testing of innovative compounds to be used for interventions in the earliest stages of neurodegeneration-dementia-Alzheimer’s disease. Presently, there are no effective interventions to delay or prevent the progression of the neurodegenerative processes that underlie the disabling symptoms of Alzheimer's dementia. From 45 proposals submitted from two countries, six researchers were awarded $1 million each to develop their proposals over two years.

Neuroinflammation Research Area (2016 Challenge)

A first-of-its-kind competition, the Part the Cloud Neuroinflammation Challenge was created to accelerate therapeutics and deepen understanding of neurodegeneration to be used in early clinical trials. Scientists around the world were invited to submit proposals that could translate into human trials of treatments targeting neuroinflammation with the goal of improving cognition in individuals with neurodegenerative diseases.

From 60 proposals submitted from 14 countries, four researchers were awarded $1 million each to develop their proposals over a two-year period. After two years, projects were evaluated, and the most outstanding project was awarded an additional $3 million to take it and the field to the next level.

Award Recipients

Back to Top